Skip to main content
Clinical Trials/NCT03263988
NCT03263988
Completed
Not Applicable

A Novel Method of Hemodynamic Monitoring by Piezocapacitative Interlayer Sensor Technology - a Pilot Study

Charite University, Berlin, Germany1 site in 1 country39 target enrollmentOctober 19, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemodynamic Instability
Sponsor
Charite University, Berlin, Germany
Enrollment
39
Locations
1
Primary Endpoint
PPV
Status
Completed
Last Updated
last year

Overview

Brief Summary

Measurement of arterial blood pressure is a basic monitoring in the perioperative setting. It is a standard monitoring to assure an adequate cerebral perfusion pressure and is a basic parameter of hemodynamic optimization. Until now standard methods for blood pressure measurement are non-invasive interval monitoring by arm cuff (Riva-Rocci) or direct, continuous and invasive by inserting an intraarterial catheter. This observational study will show, that a new non-invasive piezocapacitative-interlayer technology will make continuous blood pressure monitoring and non-invasive pulse contour analysis available.

Detailed Description

Measurement of arterial blood pressure is a basic monitoring in the perioperative setting. It is a standard monitoring to assure an adequate cerebral perfusion pressure and is a basic parameter of hemodynamic optimization. Until now standard methods for blood pressure measurement are non-invasive interval monitoring by arm cuff (Riva-Rocci) or direct, continuous and invasive by inserting an intraarterial catheter. This observational study will show, that a new non-invasive piezocapacitative-interlayer technology will make continuous blood pressure monitoring and non-invasive pulse contour analysis available. For this reason all patients will get a basic monitoring (NIBP, ECG, SpO2)

Registry
clinicaltrials.gov
Start Date
October 19, 2017
End Date
December 31, 2019
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sascha Treskatsch

Prof. Dr. med./ Deputy head of department

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • elective surgery and general anesthesia
  • age \>/= 18 years
  • any surgery in ENT/trauma/gynecology/visceral surgery/thoracic surgery/urology/neuro surgery/cardio surgery (N=10)
  • cardio surgery (N=10)
  • Transcatheter Aortic Valve Implantation (N=20)
  • cystectomy (N=10)
  • neurosurgery with an expected postoperative ICU stay \>/= 20 hours (N=10)

Exclusion Criteria

  • pregnant or breastfeeding patients
  • emergency surgery
  • participation in a clinical interventional study
  • BMI \>35 kg/m²
  • impossibility to place the ConCardiac interlayer
  • difference of blood pressure of right and left arm \> 12 mmHg
  • pAVK Fontaine IV
  • arrythmia absoluta
  • vitium cordis \>/=3
  • ejection fraction \<35%

Outcomes

Primary Outcomes

PPV

Time Frame: Duration of surgery and perioperative care (an average of 24 hours)

Percentual error of PPV \< 30% for ConCardiac between ConCardiac and PICCO

Secondary Outcomes

  • Duration of surgery(Duration of surgery (an average of 4 hours))
  • Length of hospital stay(perioperative (an average of 10 days))
  • Blood products and volume needed perioperative(perioperative (an average of 10 days))
  • Duration of anesthesia(Duration of surgery (an average of 4 hours))
  • Duration of mechanical ventilation(Duration of surgery (an average of 4 hours))
  • Duration of renal replacement therapy(perioperative (an average of 10 days))
  • intraoperative blood loss(Duration of surgery and perioperative care (an average of 24 hours))
  • Vital signs of patients/blood pressure(perioperative (an average of 10 days))
  • Vital signs of patients/heart frequency(perioperative (an average of 10 days))
  • Vital signs of patients/stroke volume(perioperative (an average of 10 days))
  • Vital signs of patients/central venous oxygen saturation(perioperative (an average of 10 days))
  • Vital signs of patients/creatinine(perioperative (an average of 10 days))
  • ICU scores (TISS)(perioperative (an average of 10 days))
  • ICU scores (SOFA)(perioperative (an average of 10 days))
  • Vital signs of patients/Cardiac index(perioperative (an average of 10 days))
  • Vital signs of patients/intrathoracic blood volume index(perioperative (an average of 10 days))
  • Vital signs of patients/central venous pressure(perioperative (an average of 10 days))
  • ICU scores (SAPS)(perioperative (an average of 10 days))
  • Vital signs of patients/systemic vascular resistance index(perioperative (an average of 10 days))
  • Vital signs of patients/extra vascular lung water index(perioperative (an average of 10 days))
  • Incidence of organ failure or complications(perioperative (an average of 10 days))
  • Vital signs of patients/pulse pressure variation(perioperative (an average of 10 days))
  • Vital signs of patients/global enddiastolic volume index(perioperative (an average of 10 days))
  • Vital signs of patients/blood gases(perioperative (an average of 10 days))
  • Vital signs of patients/Ventilator settings(perioperative (an average of 10 days))
  • Vital signs of patients/diuresis(perioperative (an average of 10 days))

Study Sites (1)

Loading locations...

Similar Trials